388 IA after Reduced-Intensity Stem Cell Transplantation (RIST)

Ref ID: 16828

Author:

RIE KOJIMA, MD, MASAHIRO KAMI, MD,YASUHITO NANNYA

Author address:

Univ. of Tokyo, Tokyo, Japan;

Full conference title:

41st Annual Meeting Infectious Diseases Society of America

Date: 9 October 2014

Abstract:

EIJI KUSUMI, MD, Toranomon Hosp., Tokyo, Japan; MIWA SAKAI, MD,
Tokyo Metropolitan Komagome Hosp., Tokyo, Japan; YUJI TANAKA, MD,
National Cancer Ctr. Hosp., Tokyo, Japan; YOSHINOBU KANDA, MD,
Univ. of Tokyo, Tokyo, Japan; SHIGESABURO MIYAKOSHI, MD,
Toranomon Hosp., Tokyo, Japan; HISAMARU HIRAI, MD, Univ. of Tokyo,
Tokyo, Japan; HISASHI SAKAMAKI, MD, Tokyo Metropolitan Komagome
Hosp., Tokyo, Japan; YOSHITOMO MUTOU, MD, Toranomon Hosp.,
Tokyo, Japan and YOICHI TAKAUE, MD, National Cancer Ctr. Hosp.,
Tokyo, Japan
Object: To evaluate the incidence and characteristics of IA following RIST in
comparison with those after CST. Methods: We examined the medical
records of 685 patients (median age, 40 y) who received allogeneic transplantation
from 1999 through 2002; 498 patients received CST, while 185 received
RIST. The primary diseases were hematological diseases (151 in RIST
and 498 in CST) and solid tumors (n34, all in RIST). In CST, the preparative
regimen included a TBI-based (n299), and a BU/CY-based (n199). In
RIST, the preparative regimen was fludarabine- (n159) or cladribine-based
(n26), with or without rabbit ATG. In CST, GVHD prophylaxis consisted of
cyclosporin (CSP) alone (n14), CSP plus short-term methotrexate (s-MTX,
n428), FK506 (n3), FK506 plus s-MTX (n44), and others (n2), while
in RIST it consisted of CSP (n125), CSP plus s-MTX (n57), and others
(n3). A diagnosis of IA was made based on EORTC criteria. Results:
Twenty-two of the 498 CST patients (4.4%) and 14 of the 185 RIST patients
(7.6%) developed IA, with the estimated one-year incidence of IA, calculatedspecies. However studies evaluating risk factors, clinical manifestations and
outcome of MSC have not been reported. Methods: We searched the microbiological
laboratory reports from 1993 to 2000 and identified 33 patients
with  2 species of Candida in one or more blood cultures within 72 h.
Sixty-six cases of C. albicans fungemia that occurred most closely in time
(before or after each case of MSC) were chosen as the control group (2:1 ratio).
Information regarding patients’ demographics, risk factors, treatment and
outcome were retrospectively collected. Results: MSC patients were more
likely to have had prolonged neutropenia prior to onset of infection (10  17
days vs. 3  6 days, p  0.02), and received chemotherapy within thirty days
prior to infection (70% vs. 42%, p  0.01). Patients with MSC more often
had an APACHE II score  16 (46% vs. 26%, p  0.05), and developed
breakthrough fungemia during antifungal prophylaxis (33% vs. 11%, p 
0.006). The response of C. albicans fungemia to single agent antifungal treatment
was significantly better than that of MSC (69% vs.35%, p 0.01). However,
the response of MSC to antifungal combination was comparable to the
response of C. albicans fungemia to single agent treatment (75% vs. 69%,
p  NS). Conclusions: MSC is more likely to occur as a breakthrough fungemia
and occurs predominantly in patients with prolonged neutropenia. Response
to single agent antifungal treatment was poor. Further studies are
needed to determine whether combination therapy can improve outcome.

Abstract Number: NULL

Conference Year: 2003

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster